Summary
Bristol-Myers Squibb Company (BMY) announced via an 8-K filing on March 4, 2003, a critical update regarding the anticipated release of its restated financial statements and related filings. The company expects to reveal the results of its previously disclosed financial restatement on Monday, March 10, 2003. This date also marks the expected filing of its amended 2001 Form 10-K and its third quarter 2002 10-Q.
Key Highlights
- 1BMY has set a specific date, March 10, 2003, for the release of its restated financial statement results.
- 2The company anticipates filing its amended 2001 Form 10-K on March 10, 2003.
- 3BMY also expects to file its third quarter 2002 Form 10-Q on March 10, 2003.
- 4This announcement provides a timeline for investors to expect resolution on previously disclosed financial statement issues.
- 5The press release detailing these events is incorporated by reference as Exhibit 99.1.
Frequently Asked Questions
This 8-K filing serves to officially announce the expected release date of Bristol-Myers Squibb's restated financial statements and related filings. It provides a clear timeline for investors regarding the resolution of previously disclosed financial issues.
Bristol-Myers Squibb expects to release the results of its financial statement restatement on Monday, March 10, 2003.
In addition to the restated financial statement results, the company expects to file its amended 2001 Form 10-K and its third quarter 2002 Form 10-Q on March 10, 2003.
A financial restatement indicates that previously issued financial statements were incorrect and have been revised. This can impact a company's reported earnings, assets, liabilities, and overall financial health, and investors need to understand the reasons for the restatement and its financial implications.